Bioavailability Study Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed State

Pfizer

Status and phase: Completed; Phase 1

Conditions: Hepatitis C Virus

Treatments: Drug: Pharmacokinetics

Study type: Interventional

Funder types: Industry

Identifiers

NCT00861458

A8121010

Details and patient eligibility

About

This study will test two different formulations. The results will be used to select formulation for phase 3.

Enrollment: 14 patients

Sex: All

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy volunteers.

Exclusion criteria

• Standard for healthy volunteers.

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

14 participants in 1 patient group

PF-00868554

Experimental group

Treatment:

Drug: Pharmacokinetics